Most Recent
Wyeth loses privilege claim over Allens docs in Merck’s vaccine patent case
Allens 2019-10-01 3:56 pm By Miklos Bolza Sydney
Wyeth has lost a bid to claim legal professional privilege over certain documents sought by Merck Sharp & Dohme as the two rivals head towards a hearing for the reopening of the Prevnar 13 patent case.
Concerns ‘poorer’ patients in vaginal mesh class action less likely to be notified of rights
Andrew Naylor 2019-09-30 9:44 pm By Amelia Birnie Sydney
The judge overseeing the Ethicon pelvic mesh class action has flagged serious public policy concerns stemming from class identification problems, amid fears that “poorer” patients in the public health system would be less likely to be notified of their rights compared to those in the private system.
Jailed former E&Y exec loses challenge to restraining orders on $150M in assets
Arthur Moses 2019-09-30 8:11 pm By Miklos Bolza Sydney
A former Ernst & Young principal jailed for at least nine years for his role in a $135 million tax fraud has lost a challenge to two NSW Supreme Court orders barring access to $150 million worth of assets.
Juno, Millennium settle patent dispute over cancer drug Velcade
Biopharmalex 2019-09-30 11:56 am By Miklos Bolza Sydney
Generic drug maker Juno Pharmaceuticals and US-based Millennium Pharmaceuticals have reached an in-principle settlement in their trans-Pacific dispute over two patents covering breakthrough anti-cancer medication Velcade.
Ariosa secures leave to appeal Sequenom win over patent for prenatal test
Appeals 2019-09-23 1:00 pm By Christine Caulfield Melbourne
US prenatal genetic test maker Ariosa Diagnostics has won its bid to appeal a ruling that its Harmony test infringed a patent owned by rival Sequenom.
Otsuka ‘deliberately’ withheld information from court, Generic Health claims
Allens 2019-09-17 9:30 pm By Miklos Bolza Sydney
Pharmaceutical company Generic Health has told the Federal Court that, on advice from their solicitors, Otsuka and Bristol-Myers Squibb "deliberately" chose not to disclose their reasons for an admission in a long-running patent case over the anti-psychotic drug Abilify, which they are now seeking to withdraw.
‘Must be April Fool’s day’: judge slams 120 common questions ‘joke’ in botched breast implant class action
Class Actions 2019-09-13 8:05 pm By Amelia Birnie Sydney
The judge overseeing a class action against The Cosmetic Institute over allegedly botched breast enhancement surgery has queried whether the plaintiffs were playing an “April Fool’s joke” after they proposed a list of 120 common questions for determination.
Judge ‘flummoxed’ about why 200 pelvic mesh cases are not a class action
AJB Stevens 2019-09-12 1:20 pm By Miklos Bolza Sydney
A Federal Court judge has expressed disbelief that hundreds of lawsuits are being pursued over allegedly defective  pelvic mesh, saying he was "absolutely flummoxed" as to why the law firm leading them hadn't considered filing a class action.
Otsuka changes tack in Abilify patent case after landmark Wyeth ruling
Allens 2019-09-11 8:49 pm By Miklos Bolza Sydney
Otsuka Pharmaceuticals and Bristol Myers-Squibb are seeking to withdraw admissions in patent litigation against Generic Health over anti-psychotic drug Abilify, following a landmark ruling last year against Wyeth that clarified the issue of compensation under the usual undertaking for damages in pharmaceutical patent cases.
Estia Health seeks to strike out ‘defective’ class action pleadings
Class Actions 2019-09-05 9:24 pm By Miklos Bolza Sydney
Aged care provider Estia Health has launched a bid to strike out the pleadings in a Phi Finney McDonald-led shareholder class action, accusing the law firm of making "speculative allegations" in the hope of strengthening its case later on.